Publications
35
Citations
1,171
Est. group size
~18
Recurring co-author estimate
Active years
13
Publishing since 2014
Preeti Sudheendra's research centers on the treatment and management of breast cancer, particularly HER2-positive and hormone receptor-positive subtypes. Their work spans clinical trials of new drug therapies (such as antibody-drug conjugates and endocrine treatments), real-world treatment patterns, side-effect management, and lifestyle factors affecting breast cancer outcomes. Much of this work involves multi-site clinical trials and retrospective cohort studies published in oncology-focused journals.
Publication output has grown substantially over the past decade, rising from about one paper per year in 2017-2021 to a sustained pace of 5-8 papers per year from 2022 through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) unresectable locally advanced or metastatic breast cancer.
Journal of Clinical Oncology · 2026
- LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.
Journal of Clinical Oncology · 2025
- Abstract P4-03-14: A review of the evidence for survival benefit of six lifestyle medicine interventions in breast cancer patients
Clinical Cancer Research · 2025
- Abstract P4-10-05: LITESPARK-029: A Phase 2, Randomized, Open-label Study of Belzutifan Plus Fulvestrant in Patients W/ Estrogen Receptor Pos, HER2-Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy
Clinical Cancer Research · 2025
- Evidence for the benefits of lifestyle medicine interventions in breast cancer survivorship
The Oncologist · 2024
- The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
npj Breast Cancer · 2024
- Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Cancer Medicine · 2024
- Association between Inflammatory Dietary Pattern and Mammographic Features
Journal of Nutrition · 2024
- Abstract PO2-14-03: Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling
Cancer Research · 2024
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Supportive Care in Cancer · 2023
- Abstract P1-02-03: Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer
Cancer Research · 2023
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Journal of Clinical Oncology · 2023
- Abstract 4639: Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence
Cancer Research · 2023
- Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens
Expert Review of Anticancer Therapy · 2022
- The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer.
Journal of Clinical Oncology · 2022
- Journal of Clinical Oncology×6
- Cancer Research×4
- Clinical Breast Cancer×3
- npj Breast Cancer×2
- Psychoneuroendocrinology×2
- Sagar Sardesai
Medicine · The Ohio State University
- Gilbert Bader
Medicine · The Ohio State University
- Patrick Schnell
Medicine · The Ohio State University
- Robert Wesolowski
Medicine · The Ohio State University
- Mathew Cherian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile